BenzingaSeptember 24, 2026 at 7:41 AM NYLast Month
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Surrozen submitted an IND application to the FDA for SZN-8141 to treat diabetic macular edema, with trial data expected in late 2027.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
